Amelioration of CKD-induced cardiomyocyte hypertrophy by pegmolesatide: involvement of JAK2/STAT3 inhibition and mitochondrial protection
{{output}}
Introduction: Cardiovascular disease represents the leading cause of mortality among patients with chronic kidney disease (CKD). CKD-associated cardiomyopathy is characterized by pathological left ventricular hypertrophy and myoc... ...